Taxus Cardium Pharmaceuticals Stock Retained Earnings
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Taxus Cardium Pharmaceuticals fundamentals help investors to digest information that contributes to Taxus Cardium's financial success or failures. It also enables traders to predict the movement of Taxus Pink Sheet. The fundamental analysis module provides a way to measure Taxus Cardium's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taxus Cardium pink sheet.
Taxus |
Taxus Cardium Pharmaceuticals Company Retained Earnings Analysis
Taxus Cardium's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Taxus Cardium Retained Earnings | (114.05 M) |
Most of Taxus Cardium's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, Taxus Cardium Pharmaceuticals has a Retained Earnings of (114.05 Million). This is 112.25% lower than that of the Biotechnology sector and 217.71% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.22% higher than that of the company.
Taxus Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.Taxus Cardium is currently under evaluation in retained earnings category among its peers.
Taxus Fundamentals
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | (1.01) % | |||
| Current Ratio | 0.08 X | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (1.13 M) | |||
| Short Ratio | 1.03 X | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 2.0 | |||
| Beta | -48.52 | |||
| Market Capitalization | 64 | |||
| Total Asset | 566.98 K | |||
| Retained Earnings | (114.05 M) | |||
| Working Capital | (3.8 M) | |||
| Current Asset | 30.78 K | |||
| Current Liabilities | 3.83 M | |||
| Net Asset | 566.98 K |
About Taxus Cardium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |